论文部分内容阅读
目的:检测经逆行胰胆管造影(ERCP)过程中所获胰液中的K-ras基因突变。探讨其在胰腺癌诊断中的作用和意义。方法:收集ERCP过程中注射促胰泌素后的胰液,应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)的方法检测胰腺良、恶性疾病胰液上清和细胞中的K-ras基因突变。结果:胰腺癌病例的胰液上清液中K-ras基因突变检出率为60.0%(18/30),细胞中的检出率为76.7%(23/30)。胰腺良性疾病胰液细胞中有15.4%(2/13)的K-ras基因突变,上清液和其他非胰腺疾病对照组胰液中无K-ras基因突变检出。胰腺癌患者的胰液中检测到K-ras基因突变明显高于胰腺良性疾病患者和对照组(P<0.001)。K-ras基因突变检出率与肿瘤的部位及大小无明显关系。结论:胰液K-ras基因突变检出对于胰腺癌的诊断具有一定作用。
OBJECTIVE: To detect K-ras gene mutations in pancreatic juice obtained during retrograde cholangiopancreatography (ERCP). To explore its role in the diagnosis of pancreatic cancer and its significance. Methods: Pancreatic fluid secreted by patients with ERCP was collected and PCR-RFLP was used to detect pancreatic juice supernatant and K-ras in pancreatic and pancreatic malignancies Gene mutation. Results: The positive rate of K-ras mutation in pancreatic juice supernatant of pancreatic cancer was 60.0% (18/30), and the positive rate in cell was 76.7% (23/30). There were 15.4% (2/13) K-ras gene mutations in pancreatic juice of pancreatic benign disease, and no K-ras gene mutation was detected in the supernatant and other non-pancreatic disease control pancreatic juice. K-ras gene mutations were detected in pancreatic juice in patients with pancreatic cancer was significantly higher than in patients with benign pancreatic disease and control group (P <0.001). K-ras gene mutation detection rate and tumor location and size no significant relationship. Conclusion: The detection of K-ras mutation in pancreatic juice may play a role in the diagnosis of pancreatic cancer.